Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial

被引：0
|
作者：
Zhu, Ying [1 ,2 ]
Jun, Min [1 ]
Fletcher, Robert A. [1 ]
Arnott, Clare [1 ,3 ]
Neuen, Brendon L. [1 ,4 ]
Kotwal, Sradha S. [1 ,5 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Sydney, Australia
[2] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Endocrinol, Chengdu, Peoples R China
[3] Univ Sydney, Royal Prince Alfred Hosp, Camperdown, Australia
[4] Univ Sydney, Royal North Shore Hosp, St Leonards, Australia
[5] Univ New South UK, Prince Wales Hosp, Randwick, Australia
来源：
DIABETES OBESITY & METABOLISM | 2025年
关键词：
chronic kidney disease; clinical outcomes; HbA1c variability; type; 2; diabetes;
D O I：
10.1111/dom.16363
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Effects of finerenone in patients with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability and duration of diabetes
    McGill, J. B.
    Agarwal, R.
    Anker, S. D.
    Bakris, G. L.
    Filippatos, G.
    Pitt, B.
    Ruilope, L. M.
    Birkenfeld, A. L.
    Caramori, M. L.
    Brinker, M.
    Joseph, A.
    Lage, A.
    Lawatscheck, R.
    Scott, C.
    Rossing, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S318 - S318
  • [2] Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry
    Luk, Andrea O. Y.
    Ma, Ronald C. W.
    Lau, Eric S. H.
    Yang, Xilin
    Lau, Winnie W. Y.
    Yu, Linda W. L.
    Chow, Francis C. C.
    Chan, Juliana C. N.
    So, Wing-Yee
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2013, 29 (05) : 384 - 390
  • [3] Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: A post hoc analysis of ACCORD trial
    Cheng, Yi
    Zou, Jun
    Chu, Rui
    Wang, Dan
    Tian, Jingyan
    Sheng, Chang-Sheng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 206
  • [4] Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial
    Oshima, Megumi
    Neuen, Brendon L.
    Jardine, Meg J.
    Bakris, George
    Edwards, Robert
    Levin, Adeera
    Mahaffey, Kenneth W.
    Neal, Bruce
    Pollock, Carol
    Rosenthal, Norman
    Wada, Takashi
    Wheeler, David C.
    Perkovic, Vlado
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11): : 903 - 914
  • [5] Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
    Cannon, Christopher P.
    Perkovic, Vlado
    Agarwal, Rajiv
    Baldassarre, James
    Bakris, George L.
    Brenner, Barry M.
    Charytan, David
    de Zeeuw, Dick
    Edwards, Robert
    Greene, Tom
    Heerspink, Hiddo J. Lambers
    Jardine, Meg
    Levin, Adeera
    Li, Jing-Wei
    Neal, Bruce
    Pollock, Carol
    Wheeler, David
    Zhang, Hong
    Zinman, Bernard
    Mahaffey, Kenneth W.
    CIRCULATION, 2019, 140
  • [6] Type 1 Diabetes: HbA1c Variability influences Progression of Kidney Disease
    Lichert, Frank
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (05) : 310 - 310
  • [7] Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7% Results From the CREDENCE Trial
    Cannon, Christopher P.
    Perkovic, Vlado
    Agarwal, Rajiv
    Baldassarre, James
    Bakris, George
    Charytan, David M.
    de Zeeuw, Dick
    Edwards, Robert
    Greene, Tom
    Heerspink, Hiddo J. L.
    Jardine, Meg J.
    Levin, Adeera
    Li, Jing-Wei
    Neal, Bruce
    Pollock, Carol
    Wheeler, David C.
    Zhang, Hong
    Zinman, Bernard
    Mahaffey, Kenneth W.
    CIRCULATION, 2020, 141 (05) : 407 - 410
  • [8] Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
    McGill, Janet B.
    Agarwal, Rajiv
    Anker, Stefan D.
    Bakris, George L.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Birkenfeld, Andreas L.
    Caramori, Maria L.
    Brinker, Meike
    Joseph, Amer
    Lage, Andrea
    Lawatscheck, Robert
    Scott, Charlie
    Rossing, Peter
    FIDELIO-DKD Investigator
    FIGARO-DKD Investigator
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1512 - 1522
  • [9] IMPACT OF HBA1C TRAJECTORIES ON CHRONIC KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES
    Low, Kiat Mun Serena
    Zhang, Xiao
    Wang, Jiexun
    Yeoh, Lee Ying
    Liu, Yan Lun
    Ang, Su Fen
    Jeevith, Babitha
    Lee, Kok Meng
    Subramaniam, Tavintharan
    Sum, Chee Fang
    Lim, Su Chi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [10] Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
    Koshino, Akihiko
    Oshima, Megumi
    Arnott, Clare
    Fletcher, Robert A.
    Bakris, George L.
    Jardine, Meg
    Mahaffey, Kenneth W.
    Perkovic, Vlado
    Pollock, Carol
    Heerspink, Hiddo J. L.
    Neuen, Brendon L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1413 - 1418
12345